hailshadow-istockphoto-com

Hailshadow / iStockphoto.com

17 September 2018Big Pharma

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

The European Patent Office (EPO) has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières (MSF).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

More on this story

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

More on this story

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

Teva fights for re-listing of inhaler patents at US appeals court

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

President Trump 2.0: Five major areas to watch